Edit concept Question Editor Create issue ticket

Immunosuppressive Therapy

Anti Rejection Therapy


  • She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose.[ncbi.nlm.nih.gov]
  • Behçet's disease is a multisystem chronic inflammatory disease generally presenting as recurrent oral-genital ulcers and uveitis. Vascular involvement is a common presentation. However, cardiac involvement is rare in this disorder.[ncbi.nlm.nih.gov]
  • We present the case of a 51-year-old woman who presented a right supraclavicular mass corresponding to lymphadenitis with atypical mycobacterium (Mycobacterium genavense).[ncbi.nlm.nih.gov]
  • A 65-year-old man presented with extrapyramidal symptoms though no symptoms typical of GCA. Imaging showed multiple ischemic strokes.[ncbi.nlm.nih.gov]
  • In conclusion, pancytopenia associated with thymoma requires medical treatment, and the evidence presented here suggests that a cyclosporine-based regimen should be considered for initial therapy.[ncbi.nlm.nih.gov]
  • We reported a complicated case of severe cutaneous cryptococcosis in a 39-year-old Vietnamese male patient with myasthenia gravis on long-term immunosuppressive therapy.[ncbi.nlm.nih.gov]
High Fever
  • A high fever and systemic lymphadenopathy developed 31 days after IST initiation. An EBV-DNA titer of 5.7 105 copies/μl was detected, and a diagnosis of EBV-LPD was made.[ncbi.nlm.nih.gov]
Persistent Cough
  • We describe a case of a woman who presented with a persistent cough, general fatigue, and a fever. Interstitial lung disease was rapidly progressive and resistant to high-dose steroid therapy.[ncbi.nlm.nih.gov]
Microscopic Hematuria
  • In fact, microscopic-hematuria was resolved in only 16 and 42 % of two-assigned groups in STOP-IgAN, respectively. Okabayashi et al. provided a timely message regarding the significance of immunosuppressive treatment of IgAN.[ncbi.nlm.nih.gov]


  • Study limitations included small sample size and heterogeneity in age and comparative treatments across the studies. CONCLUSIONS: Cyclosporin-based treatments provided a significantly better partial remission rate as compared with other therapies.[ncbi.nlm.nih.gov]
  • In a multivariable analysis, age and VSAA at the time of treatment were the independent factors for inferior survival. CONCLUSIONS: Real-world VSAA patients respond poorly to ATG which indicates the need for a different treatment approach.[ncbi.nlm.nih.gov]
  • Surgical resection by itself was generally ineffective for treatment of pancytopenia, and immunosuppressive therapy was required for bone marrow recovery.[ncbi.nlm.nih.gov]
  • The effect was sustained at more than 2 years with only two courses of treatment and an excellent tolerance. Rituximab could be proposed as a treatment of C3GP associated with antibodies interfering with complement alternative pathway.[ncbi.nlm.nih.gov]
  • OBJECTIVES: To estimate the safety of live vaccinations in patients with immune-mediated inflammatory diseases (IMID) or solid organ transplantation (SOT) on immunosuppressive treatment and in patients after bone-marrow transplantation (BMT).[ncbi.nlm.nih.gov]


  • This study aims to test whether immunosuppressive therapy is effective in reducing the complication of the operation and improve the prognosis.[ncbi.nlm.nih.gov]
  • KEYWORDS: Aplastic anemia; Immunosuppressive therapy; Paroxysmal nocturnal hemoglobinuria; Prognosis; Telomere length[ncbi.nlm.nih.gov]
  • ZAP70 is also overexpressed in some individuals with chronic lymphocytic leukaemia, and these individuals have an especially poor prognosis. ZAP70 might therefore also be a useful therapeutic target in these patients.[ebi.ac.uk]
  • We conclude that in children without a MSD treatment with combined IST and G-CSF converts the former bad prognosis factor severe granulocytopenia into an indicator of better response and survival.[bloodjournal.org]
  • However, prognosis is much worse, if PVG is detected with PI.[medcraveonline.com]


  • Whether anti-GAD antibodies have an etiological role in these neurological disorders or simply serve as disease markers is unclear.[ncbi.nlm.nih.gov]
  • A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent.[ncbi.nlm.nih.gov]


  • Spallanzani, Rome, Italy. 5 Unit of Clinical Epidemiology, IRCCS INMI L. Spallanzani, Rome, Italy. 6 Department of Cardiac Surgery, European Hospital, Rome, Italy.[ncbi.nlm.nih.gov]
Sex distribution
Age distribution


  • Abnormal cytotoxic T-cell activation with cytokine release is a possible pathophysiology. We present the case of a 16-month-old Japanese male who developed HAAA following living-donor liver transplantation for fulminant hepatitis.[ncbi.nlm.nih.gov]


  • To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects.[ncbi.nlm.nih.gov]
  • It is hoped that these new agents and personalized immunosuppression will provide for less toxic regimens that are effective in preventing both acute and chronic allograft rejection.[ncbi.nlm.nih.gov]
  • Therefore, it is important to immunize children to minimize vaccine-preventable infections. However, there is a paucity of data on immune response to vaccines in patients with IBD.[ncbi.nlm.nih.gov]
  • CONCLUSION: The preliminary results indicate that the risk of NMSC in RTRs is significantly higher than in the general population and thus emphasize the need to improve preventive strategies in the Czech transplant population. 2016 Wiley Periodicals,[ncbi.nlm.nih.gov]
  • CONCLUSION: We conclude that the immunosuppressive maintenance therapy after transplantations seems to be sufficient to prevent de novo ERT inhibition in ERT-naïve patients.[ncbi.nlm.nih.gov]

Ask Question

5000 Characters left Format the text using: # Heading, **bold**, _italic_. HTML code is not allowed.
By publishing this question you agree to the TOS and Privacy policy.
• Use a precise title for your question.
• Ask a specific question and provide age, sex, symptoms, type and duration of treatment.
• Respect your own and other people's privacy, never post full names or contact information.
• Inappropriate questions will be deleted.
• In urgent cases contact a physician, visit a hospital or call an emergency service!